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Abstract
Background: Paediatric focal intracranial suppurative infections are uncommon but cause significant mortality and
morbidity. There are no uniform guidelines regarding antibiotic treatment. This study reviewed management in a
tertiary healthcare centre in the United Kingdom and considers suggestions for empirical treatment.
Methods: A retrospective, single-centre cohort review of 95 children (< 18 years of age) with focal intracranial
suppurative infection admitted between January 2001 and June 2016 in Newcastle upon Tyne, United Kingdom.
Microbiological profiles and empirical antibiotic regimens were analysed for coverage, administration and duration
of use. Mortality and neurological morbidity were reviewed. Data was analysed using t-tests, Mann-Whitney U tests,
independent-samples median tests, and χ2-tests where appropriate. P-values < 0.05 were considered statistically
significant.
Results: Estimated annual incidence was 8.79 per million. Age was bimodally distributed. Predisposing factors were
identified in 90.5%, most commonly sinusitis (42.1%) and meningitis (23.2%). Sinusitis was associated with older
children (p < 0.001) and meningitis with younger children (p < 0.001). The classic triad was present in 14.0%.
43.8% of 114 isolates were Streptococcus spp., most commonly Streptococcus milleri group organisms. Twelve
patients cultured anaerobes.
Thirty one empirical antibiotic regimens were used, most often a third-generation cephalosporin plus
metronidazole and amoxicillin (32.2%). 90.5% would have sufficient cover with a third generation cephalosporin
plus metronidazole. 66.3% converted to oral antibiotics. Median total antibiotic treatment duration was 90 days
(interquartile range, 60–115.50 days).
Mortality was 3.2, 38.5% had short-term and 24.2% long-term neurological sequelae.
Conclusions: Paediatric focal intracranial suppurative infection has a higher regional incidence than predicted from
national estimates and still causes significant mortality and morbidity. We recommend a third-generation
cephalosporin plus metronidazole as first-choice empirical treatment. In infants with negative anaerobic cultures
metronidazole may be discontinued.
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Introduction
Focal intracranial suppurative infections are serious con-
ditions rarely seen in children. [1–5] They are divided in
three categories: brain abscess (BA), subdural empyema
(SDE), and extradural empyema (EDE). In the pre-anti-
biotic era, mortality reached nearly 100% [6], decreasing
to around 36–60% in the 1970s when antibiotics became
more readily available. [3, 7] Since then mortality has
dropped further, ranging 3.7–24%, as computed tomog-
raphy was introduced and cranial imaging improved,
and metronidazole became part of most standard empir-
ical regimens in the 1980s. [7–14]
Although mortality has dropped, these infections con-
tinue to cause significant mortality and morbidity, and
can lead to rapid patient deterioration, thus adequate
diagnostics and early aggressive treatment are crucial to
optimise chances of complete recovery. [4, 9, 10, 14–16]
The annual estimated incidence is 4–5.3/1,000,000 [2,
12], with higher incidences in developing countries. [15,
17] For the United Kingdom (UK) this translates to ap-
proximately 3 paediatric cases per tertiary healthcare
centre annually.
In 74.4–91.6% a predisposing factor can be deter-
mined. [7, 14, 18] Compared to adults, congenital heart
disease (CHD) and immunosuppression occur more fre-
quently in children. [2] Other common predispositions
in children are meningitis and sinusitis. [4, 9, 16, 17] Pa-
tients can present with a variety of symptoms. The clas-
sic triad consisting of headache, fever, and focal
neurological deficits is reported in 8.4–20% of children.
[3, 12, 14, 18] Treatment is multidisciplinary consisting
of antibiotics and neurosurgery. [3, 5] Neurosurgical
intervention aids pathogen identification, reduces lesion
size and decompresses, aiming to reduce effects on sur-
rounding structures. [19]
Several microorganisms have been implicated, but
most commonly cultured are Streptococci and Staphylo-
cocci. [1, 2, 10, 12, 14, 16, 20–22] 11.1–33% of patients
grow anaerobic species [3, 7, 12], and 14.3–27% of BAs
is polymicrobial. [11, 14] Empirical antibiotic treatment
is broad-spectrum to cover these organisms, and ratio-
nalised on microbiological guidance.
There is no standardised empirical antibiotic treatment.
[9, 16, 23, 24] Often first-choice empirical treatment is a
third-generation cephalosporin plus metronidazole. [12, 19]
These antibiotics have adequate pharmacokinetics and
pharmacodynamics to achieve therapeutic concentrations
within the central nervous system. [25]
In the UK there are currently no national guidelines re-
garding treatment of paediatric suppurative intracranial
infections. [12] Internationally proposed consensus docu-
ments and guidelines are controversial [19, 23, 24, 26], be-
cause they are based on combined adult and paediatric
literature. Paediatric evidence remains sparse, mainly
consisting of case-series with small patient popula-
tions. [3, 11, 18, 21]
Published guidelines suggest antibiotic treatment for
6–8 weeks by intravenous administration only. [24]
However, guidelines from The Infection in Neurosurgery
Working Party of the British Society for Antimicrobial
Chemotherapy [27] recommend 1–2 weeks of intraven-
ous administration and to consider conversion to oral
administration, depending on clinical response and de-
creasing C-reactive protein (CRP), to complete the anti-
biotic course.
This study evaluated local management of paediatric
focal intracranial suppuration and reviewed antibiotic
practice in order to consider empirical antibiotic
guidelines.
Methods
This single-centre retrospective cohort study reviewed
paediatric patients with BA, SDE, and EDE, admitted to
the Great North Children’s Hospital (GNCH), a tertiary
healthcare centre for paediatric infectious diseases and
neurosurgery in the North East of England between
January 2001 and June 2016. Local Caldicott approval
was obtained.
Patient identification
Eligible cases were identified by assessing the paediatric
infectious diseases, intensive care (PICU) and neurosur-
gery records, the previously described local cohort [9],
and the hospital clinical coding database.
The following World Health Organization International
Classification of Disease Codes [28], tenth revision, were
used: G06.0 Intracranial abscess and granuloma, G06.2
Extradural and subdural abscess, unspecified, and G07
Intracranial and intraspinal abscess and granuloma in dis-
eases classified elsewhere.
Cases were included if the patient was < 18 years of
age on admission, had a confirmed diagnosis according
to clinical information, and had diagnosis confirmation
by radiology.
Data collection
Data was collected from medical records and electronic
systems used within the hospital. Data was recorded on
patient demographics, admission duration, confirmed
diagnosis, presenting symptoms, symptom duration be-
fore admission, predisposing factors, laboratory and
microbiology results, antibiotics, neurosurgical manage-
ment, morbidity and mortality.
Microbiology
Microbiological data was collected from cultures taken
during admission. This included blood, cerebrospinal
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fluid (CSF), intracranial pus and paranasal sinus
cultures.
Positive cultures were defined as cultures with micro-
organism growth or positive polymerase chain-reaction
(PCR) (PCR panel: Streptococcus spp., Neisseria meningiti-
des, Fusobacterium spp., Aspergillus spp. Staphylococcus
spp). Antibiotic resistance patterns were recorded.
Cases without growth in any cultures, had cultures
reassessed. As per microbiology protocol, gram stains of
every sample are examined microscopically before cul-
turing and sent for PCR identification if no growth is ob-
served after incubation. If either test was found positive,
the culture was considered positive. Otherwise, the cul-
ture was considered negative. Due to changes in the
microbiology protocol between 2001 and 2016, not all
samples were sent for PCR in growth-negative cases
owing to increasing availability of PCR since 2004 only.
Statistical analysis
Data was analysed with SPSS®Statistics, version 22 (IBM
Corporation, Armonk, New York). Normality was assessed
with the Shapiro-Wilk test. Normally distributed data was
analysed with unpaired t-tests or one-sample t-tests. Not
normally distributed data was analysed with Mann-Whitney
U tests and independent-samples median tests. χ2-tests were
used where appropriate. P-values < 0.05 were considered
statistically significant.
Results
107 eligible cases were identified. 7 cases were excluded
due to incorrect coding, case notes were unavailable for
3, and 2 patients were primarily treated in other health-
care centres. 95 cases were suitable for analysis, of which
2 had chronic granulomatous disease (CGD) whose data
were only suitable for diagnosis, predisposing factors
and mortality analysis (Fig. 1).
This centre treated on average 6.13 cases annually. All
patients originated from the GNCH catchment area. The
child population (aged 0–19 years) of this area was
697,200 in 2014. [29, 30] This leads to an estimated an-
nual incidence of 8.79/1,000,000.
Patient demographics
There were 60 males (63.2%). Median admission age was
10.21 years (interquartile range (IQR), 1.57–12.67 years) and
was bimodally distributed (Figure 2). Age at presentation
was not significantly different between males and females
(median, 8.73 and 11.53 years, respectively, p= 0.172). There
was no association between age or sex and type of intracra-
nial suppurative infection.
Diagnosis and localisation
All patients underwent cranial imaging with contrast.
33/95 patients had BA (34.7%), 46/95 had SDE (48.4%),
2/95 had EDE (2.2%), 6/95 had BA and SDE (6.3%), 1/95
had BA and EDE (1.1%), and 7/95 had SDE and EDE
(7.4%). 13/40 (32.5%) had multiple abscesses. The majority
of brain abscesses was located in the frontal lobe (50%).
Predisposing factors
Predisposing factors were identified in 86 patients (90.5%).
Most common were sinusitis (42.1%) and meningitis (23.2%)
(Table 1). 27/40 sinusitis patients were in the 10–15 years
age group and 16/22 meningitis patients were in < 1-year age
group (Fig. 3). Meningitis patients were younger compared
to children with other predisposing factors (median, 0.46 ver-
sus 11.55 years, p < 0.001) and sinusitis patients were older
compared to children with other predisposing factors (me-
dian, 12.47 versus 2.64 years, p < 0.001). Other predisposing
factors were not associated with age.
Presenting symptoms
For 89 patients symptom duration was documented and
the median duration was 7 days (IQR 5–14 days). Most
common symptoms were history of fever (66.7%), vomit-
ing (66.7%), and headache (58.1%) (Table 2). The clas-
sical triad combining these symptoms was present in 13
patients (14.0%).
Microbiology
60/93 patients (74.2%) had blood cultures taken before
antibiotic treatment and 17 were positive (28.3%). CSF
cultures were taken in 38/93 patients (40.8%) and 18
were positive (47.4%). Intracranial pus was cultured in
70/93 patients (75.3%) and positive for 52 (74.3%). Para-
nasal sinus cultures were taken from 23/93 patients
(24.7%) and positive in 14 (60.9%). Overall 114 isolates
of 53 species were grown amongst 69 patients (Fig. 4).
50/114 isolates were Streptococcus spp., of which Strepto-
coccus milleri group organisms and Streptococcus pneu-
moniae were most often isolated, 25 and 8 times
respectively. Streptococcus pyogenes was isolated 5 times.
16/114 isolates were Staphyloccus spp., of which 9 Sta-
phyloccus aureus, and 7 coagulase-negative Staphylococci.
Coagulase-negative Staphylococci were only considered
relevant if isolated from intracranial pus culture.
6 culture-negative patients had PCR-positive samples
for either Streptococcus intermedius, Streptococcus pneu-
moniae, Fusobacterium nucleatum, Neisseria meningitidis
or Aspergillus spp. Additionally, 4 patients had microscop-
ically positive samples for gram-positive cocci. In 13 pa-
tients all microbiological investigations were negative.
In 21 patients (22.6%) multiple microorganisms were
isolated from different sites (range, 2–6 microorganisms)
and 12 patients (12.9%) had polymicrobial abscess or
empyema (range, 2–6 microorganisms). 21 anaerobic
species were isolated from 12 patients, most commonly
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Prevotella spp. Anaerobic microorganisms were only iso-
lated from children aged 1–15 years.
Antibiotic treatment
92 patients were started on antibiotics and 3 on antifun-
gals. 90 patients were started on empirical antibiotic reg-
imens and two on quadruple therapy for tuberculosis.
Empirical antibiotic regimens consisted of 1–4 antibi-
otics and all but tuberculostatics were initially adminis-
tered intravenously. 17 different antibiotics were given in
31 empirical regimens.
Most commonly administered empirical regimens con-
sisted of a third-generation cephalosporin, metronida-
zole and amoxicillin in 29/90 patients (32.2%). 7 patients
Fig. 1 Flowchart of Patient Identification
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had a third-generation cephalosporin alone, 15 had a
third-generation cephalosporin plus metronidazole, and
13 a third-generation cephalosporin plus metronidazole
and a third antibiotic other than amoxicillin.
Antibiotic changes occurred in 86 patients (95.6%).
Reasons documented included microbiology results,
antibiotic sensitivities, adverse reactions, and conversion
to oral administration. 13 patients (14.4%) developed
antibiotic-related rashes and 6 antibiotic-related neutro-
penia. 18 patients required additional teicoplanin for
presumed central line infections.
61 patients were converted to oral antibiotics (66.3%)
and 5 children received intrathecal antibiotics. Most oral
regimens consisted of amoxicillin, amoxicillin/clavulanic
acid, and/or metronidazole. Overall, 22 different antibi-
otics were used in this cohort.
Total duration of antibiotic treatment was docu-
mented for 89 patients, intravenous duration for 90 and
oral treatment for 61. For 3 patients, antibiotic treat-
ment duration was unclear; 1 had an unclear end of
intravenous treatment, and 2 an unclear end of oral
treatment.
6 patients were excluded from antibiotic treatment
duration analysis; 2 had Mycobacterium turberculosis
and 2 had Actinomyces spp. infection, both known to re-
quire prolonged antibiotic treatment, one had complex
Clostridium septicum infection requiring individualised
prolonged antibiotic treatment and one patient died 9
days into treatment, not completing the intended anti-
biotic course.
Median total duration of antibiotic treatment was 92
days (IQR, 59–119 days), median duration of intravenous
antibiotics 46.50 days (IQR, 25–71.50 days), and median
duration of oral antibiotics 47 days (IQR, 38–77 days).
Antibiotic coverage
Sixty-nine patients on empirical antibiotics had growth-
positive cultures. For 63/69 patients full sensitivities
were available and antibiotic coverage was analysed.
Chosen empirical regimens provided sufficient coverage
in 60/63 patients (95.2%). 2 patients had resistant microor-
ganisms; one a metronidazole-resistant Dialister pneumo-
sintes, and one an amoxicillin and cefotaxime-resistant
Ochrobactrum anthropi. 31/63 patients (49.2%) had an
empirical regimen containing a third-generation cephalo-
sporin or carbapenem plus amoxicillin, of which 30 did
not require amoxicillin for additional coverage. One pa-
tient for whom amoxicillin provided necessary coverage
grew a cefotaxime-resistant, amoxicillin-sensitive Entero-
coccus faecalis. The combination of a third-generation
cephalosporin plus metronidazole would have been suffi-
cient in 57/63 patients (90.5%), and a third-generation
cephalosporin alone in 51/63 (81.0%). Meropenem plus li-
nezolid would have covered 60/63 patients (95.2%). Linez-
olid was analysed rather than vancomycin because of
superior CNS penetration which would be preferred des-
pite potential side effects of linezolid (bone marrow sup-
pression and neuropathy), as these are usually not
observed in the first four weeks of treatment [25].
Neurosurgery
75/93 patients required neurosurgery (80.6%). 35 pa-
tients underwent craniotomy, 30 burr hole drainage, 4
craniectomy, 4 aspiration via fontanelle, and 2 stereo-
tactic aspiration. Median duration to neurosurgery
was one day from admission (IQR 0–3 days). 30 pa-
tients required repeated neurosurgical interventions
(maximum 6).
Fig. 2 Case Distribution in Age Groups
Table 1 Predisposing Factors (N = 95)
Predisposing Factor N (%) Predisposing Factor N (%)
Sinusitis 40 (42.1%) Immunocompromised 4 (4.2%)
Meningitis 22 (23.2%) Congenital Brain Cyst 2 (2.1%)
Mastoiditis 11 (11.6%) Congenital Heart Disease 1 (1.1%)
Otitis media 7 (7.4%) Dental Infection 1 (1.1%)
Previous neurosurgery 5 (5.3%) Haemolytic Uraemic Syndrome 1 (1.1%)
Distant Infection 5 (5.3%) None Identified 9 (9.5%)
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Outcome
Mortality in this cohort was 3.2%. Median duration of
hospitalisation was 23 days (IQR, 15.5–34.5 days). Chil-
dren exclusively treated with intravenous antibiotics did
not require longer hospitalisation than children converted
to oral antibiotics (median 25 versus 22 days, p = 0.266).
Follow-up data was available for 87/92 surviving pa-
tients (93.4%). One patient was lost to follow-up due to
emigration and 4 had an unclear follow-up duration. 10
patients were still in follow-up. For patients with com-
pleted follow-up the median duration was 7.99months
(IQR 4.92–12.64months). Recurrence of intracranial sup-
purative infection occurred once in a child who developed
bone flap osteomyelitis post-antibiotic treatment.
Thirty-five children (38.0%) had short-term neurological
sequelae (< 6months post-discharge) not present at initial
presentation and 22 children (23.9%) long-term neuro-
logical sequelae (≥6months post-discharge). Most com-
mon were seizures and hemiplegia (Table 3). Fifteen
patients resolved short-term neurological sequelae within
6months and 2 developed neurological sequelae ≥6
months post-discharge.
Median symptom duration before admission was shorter
for children with short-term neurological sequelae (6 versus
10 days, p = 0.002) and with long-term neurological seque-
lae (5 versus 8.50 days, p = 0.037), compared to patients
without neurological sequelae. Initial Glascow Coma Scale
(GCS) was not recorded for all patients, prohibiting mean-
ingful statistical analysis. Although there seemed to be a
trend for patients with a low GCS to have worse outcomes,
also patients with maximal GCS, but who deteriorated rap-
idly after admission tended to have worse outcomes.
Fig. 3 Predisposing Factors by Age Group
Table 2 Presenting Symptoms (N = 93)
Symptom N (%) Symptom N (%)
Fever (History) 62 (66.7%) Nuchal Rigidity 14 (15.1%)
Vomiting 62 (66.7%) Rhinorrhoea 13 (14.0%)
Headache 54 (58.1%) Papilloedema 11 (11.8%)
Focal Neurological Deficit 35 (37.6%) Photophobia 10 (10.8%)
Fever (> 38.0 °C) 33 (35.5%) Nausea 7 (7.5%)
Lethargy 33 (35.5%) Increased Head Circumference 5 (5.4%)
Altered Level of Consciousness 27 (29.0%) Behavioural Change 5 (5.4%)
Seizure 22 (23.7%)
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Conversion to oral antibiotics was not associated with
development of short- (p = 0.959) or long-term (p =
0.135) neurological sequelae, compared to children ex-
clusively on intravenous antibiotics.
Patients with unusual clinical courses or where S. pneumo-
niae was cultured were investigated for immunodeficiencies.
Only one patient with underlying immunodeficiency was
identified.
Discussion
Our study is the largest single-centre study assessing local
management of paediatric focal intracranial suppurative
Fig. 4 Distribution of Isolated Pathogens in Growth-Positive Cultures (N = 114)
Table 3 Neurological Sequelae < 6months and ≥ 6 months post-discharge not present at admission
Neurological
sequelae
< 6 months post-
discharge (n = 92)
≥6 months post-
discharge (n = 92)
Neurological
sequelae
< 6 months post-
discharge (n = 92)
≥6 months post-
discharge (n = 92)
Any sequelae 35 (38.0%) 22 (23.9%) Any sequelae 35 (38.0%) 22 (23.9%)
Seizures 10 (28.6%) 11 (50%) Nystagmus 2 (5.7%) 2 (9.1%)
Hemiplegia 6 (17.1%) 4 (18.1%) Torticollis 2 (5.7%) –
Diplopia 4 (11.4%) 3 (13.6%) Dysdiadochokinesis 1 (2.9%) –
n.VII palsy 4 (11.4%) 3 (13.6%) Hearing loss 1 (2.9%) 2 (9.1%)
Speech abnormality 4 (11.4%) 1 (4.5%) Hemianopia 1 (2.9%) 2 (9.1%)
Gait abnormality 3 (8.6%) 3 (13.6%) Neurodevelopmental
delay
1 (2.9%) 1 (4.5%)
Dysphasia 3 (8.6%) 3 (13.6%) Memory difficulties 1 (2.9%) 2 (9.1%)
Delayed motor
development
2 (5.7%) – Visual discrimination
difficulty
1 (2.9%) –
Hemiparesis 2 (5.7%) 2 (9.1%) Learning difficulties – 2 (9.1%)
Hydrocephalus 2 (5.7%) 3 (13.6%) Concentration
difficulties
– 1 (4.5%)
n. VI palsy 2 (5.7%) – Cerebral palsy – 1 (4.5%)
Neuropathic pain 2 (5.7%) 1 (4.5%)
van der Velden et al. BMC Pediatrics          (2019) 19:130 Page 7 of 10
infection in order to analyse effectiveness of local manage-
ment, identify causative pathogens and guide empirical
antibiotic therapy. Our findings extended on Cole et al. [9]
and demonstrated similarities and differences compared
to case-series by other centres.
Our estimated annual incidence was higher than the
5.3/1,000,000 previously reported in the UK. [12] The
annual incidence in this tertiary centre was three times
higher than in other developed countries. [3, 11, 16, 18,
20, 21] Our local annual incidence showed similarity
with a Cameroonian study. [17] Reasons for this may lie
in high rates for non-specific symptoms and subsequent
lower suspicion for focal intracranial suppuration, and
less health-seeking behaviour for upper respiratory tract
infections. Median age at admission and bimodal age
distribution are consistent with other studies. [12, 17]
Mortality in this cohort was 3.2%, which is at the
lower end of the spectrum previously reported (2.6–
21.4%). [3, 7, 11, 12, 15–18, 20–22] Neurological mor-
bidity remains a significant problem, yet rates concur
with other centres. [11, 12, 17, 18, 31] Long-term neuro-
logical sequelae affected a smaller proportion than
short-term neurological sequelae, but might be underre-
ported as follow-up in tertiary care ended, and neuro-
psychological effects and mild cognitive impairments are
difficult to diagnose.
Predisposing factors were identified in 90.5%. Meningi-
tis was associated with younger and sinusitis with older
age, which is unsurprising given sinus maturation. High
rates of sinusitis and meningitis may be explained by the
number of SDE patients in this cohort. There is an asso-
ciation between SDE and meningitis and sinusitis, previ-
ously demonstrated by Legrand et al. [16] Adolescent
patients are more at risk for intracranial complications
of sinusitis compared to younger children and adults,
and sinusitis patients were mostly adolescents. [32] Ado-
lescents are more likely to develop intracranial extension
of sinusitis, as vascularity and blood supply of diploic
veins is known to be increased compared to adults. [33]
CHD as a predisposing factor in this study was rare.
This has been reported by other centres [3, 17, 31], al-
though some centres report CHD as their main predis-
posing factor in 20.8–40%. [7, 18, 20, 21]
35.6% had focal neurological deficits at presentation
and 23.7% seizures at admission. This is similar to other
centres [11, 17, 18], although rates go up to 53% [12]
and 48% [21] respectively. In this study the most com-
mon symptoms were non-specific. The classic triad was
seldom seen. This is in accordance to literature from de-
veloped countries [3, 18], while developing countries see
the triad in up to 52% [17]. Children with poorer out-
come had shorter symptom duration, and tended to have
more severe altered levels of consciousness, which may
be attributed to more rapid deterioration. Although
otorhinolaryngological infections were prevalent in this
cohort, concurrent symptoms were not often reported
and may be underreported since patients often had more
severe presenting clinical features.
Streptococci were most commonly isolated with
Streptococcus milleri group organisms as most common
species. The second largest group were Staphylococci, al-
though it is debatable how many coagulase-negative iso-
lates were pathogenic. The predominance of Streptococci
has been described previously in the UK [12], as well as
in other countries [3, 7, 11, 16, 20–22, 31]. 12.9% of iso-
lates were anaerobic which concurs with published lit-
erature. [11, 12] Interestingly Prevotella spp. were most
common, whereas other centres report Fusobacterium
spp. as the most common anaerobic isolate. [3, 11, 20]
This study showed great variability in empirical regimens
and in antibiotic treatment duration. This has been noted
previously [3, 11, 12], and demonstrates the lack of uniform
guidelines and potentially a change in practice over the 15
years covered by the study. Nonetheless, chosen regimens
provided sufficient coverage in the majority of patients.
Broad-spectrum antibiotics remain necessary before micro-
biology results, as gram-positive, gram-negative and anaer-
obe microorganisms were all cultured in this cohort.
Combinations including third-generation cephalosporins
plus metronidazole were successful in the majority of pa-
tients. 90.5% of patients with growth-positive cultures would
have been sufficiently covered with a third-generation ceph-
alosporin plus metronidazole, and most patients with nega-
tive cultures improved clinically on this regime. Therefore,
we recommend this regime as first-choice empirical anti-
biotic treatment. Despite meropenem plus linezolid covering
a greater proportion, this regimen should be reserved for se-
vere or treatment non-responsive cases. Over the 15.5-year
period, there have not been any anaerobic pathogens cul-
tured in the < 1 and > 15-years age groups. In infants, the
routine use of metronidazole might be reconsidered if anaer-
obic cultures are negative. The > 15-years age group was too
small to make a similar recommendation.
Strengths and limitations
This study has the largest number of paediatric patients
in a single-centre cohort. This enabled us to comprehen-
sively review the management of paediatric focal intra-
cranial suppurative infections.
Limitations lie in the retrospective nature of the study,
leading to potential information bias. 2.8% of cases had
to be excluded because of unavailable case notes.
Long-term complications possibly have been underre-
ported as follow-up ended and patients may have pre-
sented with sequelae to local hospitals or have subtler,
underrecognised, neuropsychological sequelae. The
single-centre aspect of this study makes results difficult
to generalise, and there are differences compared to
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other single-centre studies. However, it shares similar-
ities with other centres and provides additional data to
assist clinical choices in centres with similar microbio-
logical profiles and facilities.
In conclusion, paediatric focal intracranial suppurative
infection continues to cause significant mortality and
morbidity. Although uncommon, it occurs more fre-
quently in the North East of England than previously re-
ported in developed countries. Empirical antibiotic
regimens should provide broad-spectrum coverage and
we recommend a third-generation cephalosporin plus
metronidazole. Meropenem and linezolid should be re-
served for severe and complex cases. In infants the use
of metronidazole might be reconsidered if the microbiol-
ogy results are negative for anaerobes. Optimum dur-
ation of antibiotic treatment remains unclear. A
multi-centred, prospective randomised controlled trial
would be required to answer this question. Further re-
search should focus on the identification of factors caus-
ing the local higher occurrence paediatric focal
intracranial suppurative infection and the development
of guidelines for antibiotic treatment.
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